Metabolic syndrome and symptom burden in allogeneic hematopoietic stem cell transplantation survivors.

Autor: Trinh JQ; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Nilles JD; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Ellithi M; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA., Haddadin MM; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA., Maness-Harris L; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA., Gundabolu K; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA., Wichman CS; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA., Bhatt VR; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.

Publikováno v: Future oncology (London, England) [Future Oncol] 2024 Nov 24, pp. 1-6. Date of Electronic Publication: 2024 Nov 24.

Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia.

Autor: Pan Q; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA., Xin X; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA., Mahto S; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA., Dong Y; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA., Kumar V; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA., Hyde RK; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA., Gupta N; Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA., Bhatt VR; Division of Hematology and Oncology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: vijaya.bhatt@unmc.edu., Mahato RI; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: ram.mahato@unmc.edu.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Nov 06; Vol. 32 (11), pp. 4058-4074. Date of Electronic Publication: 2024 Oct 05.

Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis.

Autor: Farhadfar N; Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, San Antonio, TX., Rashid N; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.; Department of Bone Marrow Transplant, Southern California Permanente Medical Group, Duarte, CA., Chen K; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., DeVos J; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Wang T; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI., Ballen K; Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL., Bhatt VR; The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE., Hamilton BK; Blood and Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Hematti P; Division of Hematology/Oncology, BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Gadalla SM; Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Rockville, MD., Solomon SR; Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA., El Jurdi N; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Lee CJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., MacMillan ML; Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN., Rangarajan HG; Department of Pediatric Hematology, Oncology & Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH., Schoemans H; Department of Hematology, University Hospitals Leuven, Leuven, Belgium.; Department of Public Health and Primary Care, ACCENT VV, KU Leuven, University of Leuven, Leuven, Belgium., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN., Spellman SR; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN., Wingard JR; Division of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL., Lee SJ; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

Publikováno v: Blood advances [Blood Adv] 2024 Sep 24; Vol. 8 (18), pp. 4963-4976.

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.

Autor: Jain T; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Estrada-Merly N; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Salas MQ; Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology, Hospital Clínic de Barcelona, Barcelona, Spain., Kim S; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI., DeVos J; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Chen M; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Fang X; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI., Kumar R; Princess Margaret Cancer Centre, Toronto, Canada., Andrade-Campos M; Hospital del Mar Research Institute, Barcelona, Spain., Elmariah H; Department of Bone Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Center and Research Institute, Tampa, FL., Agrawal V; Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Aljurf M; Oncology Center, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia., Bacher U; Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Badar T; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL., Badawy SM; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL.; Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL., Ballen K; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL., Bhatt VR; The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE., Bredeson C; The Ottawa Hospital Transplantation and Cellular Therapy Program and Ottawa Hospital Research Institute, Ottawa, ON, Canada., DeFilipp Z; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Dholaria B; Vanderbilt University Medical Center, Nashville, TN., Farhadfar N; Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, TX., Farhan S; Henry Ford Health System Stem Cell Transplant & Cellular Therapy Program, Detroit, MI., Gandhi AP; Division of Hematology/Medical Oncology, Oregon Health and Science University, Portland, OR., Ganguly S; Houston Methodist Hospital and Neal Cancer Center, Houston, TX., Gergis U; Division of Hematological Malignancies, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Hamad N; Department of Hematology, St. Vincent's Hospital Sydney, Australia.; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.; School of Medicine, University of Notre Dame, Sydney, Australia., Hamilton BK; Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Inamoto Y; Department of BMT & Cellular Therapy, Fujita Health University School of Medicine, Toyoake, Japan., Iqbal M; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL., Jamy O; University of Alabama at Birmingham, Birmingham, AL., Juckett M; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Kharfan-Dabaja MA; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL., Krem MM; Kansas City VA Medical Center, Kansas City, MO., Lad DP; Leukemia/Bone Marrow Transplant Program of British Columbia, Division of Hematology, Department of Medicine, The University of British Columbia, Vancouver, Canada., Liesveld J; Department of Medicine, University of Rochester Medical Center, Rochester, NY., Al Malki MM; City of Hope National Medical Center, Duarte, CA., Malone AK; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Murthy HS; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL., Ortí G; Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain., Patel SS; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Pawarode A; Adult Blood and Marrow Transplantation and Cellular Therapy, Rogel Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI., Perales MA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, New York, NY., van der Poel M; Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Ringden O; Translational Cell Therapy Group, Clinical Science, Intervention, and Technology Karolinska Institutet, Stockholm, Sweden., Rizzieri DA; Novant Health Cancer Institute, Winston Salem, NC., Rovó A; Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Savoie ML; University of Calgary, Calgary, AB, Canada., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Solh M; Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA., Ustun C; Division of Hematology, Oncology, and Cell Therapy, RUSH University, Chicago, IL., Verdonck LF; Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands., Wingard JR; Division of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL., Wirk B; Virginia Commonwealth University, Massey Comprehensive Cancer Center, Richmond, VA., Bejanyan N; Department of Bone Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Center and Research Institute, Tampa, FL., Jones RJ; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Nishihori T; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.; Department of Oncologic Sciences, Morsani College of Medicine, University South of Florida, Tampa, FL., Oran B; Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX., Nakamura R; City of Hope National Medical Center, Duarte, CA., Scott B; Fred Hutchinson Cancer Research Center, Seattle, WA., Saber W; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Gupta V; Princess Margaret Cancer Centre, Toronto, Canada.

Publikováno v: Blood advances [Blood Adv] 2024 Aug 27; Vol. 8 (16), pp. 4281-4293.

Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT.

Autor: Sureda A; Clinical Hematology Department, Institut Català d'Oncologia-L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain. asureda@iconcologia.net., Carpenter PA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Bacigalupo A; Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., Bhatt VR; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA., de la Fuente J; Department of Paediatrics, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.; Department of Immunology & Inflammation, Imperial College London, London, UK., Ho A; Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore., Kean L; Stem Cell Transplantation Program. Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lee JW; Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea., Sánchez-Ortega I; EBMT Medical officer, EBMT executive office, Barcelona, Spain., Savani BN; Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Schetelig J; Medical Department I, University Hospital Carl Gustav Carus. TU Dresden & DKMS Group, Clinical Trials Unit, Dresden, Germany., Stadtmauer EA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Takahashi Y; Department of Pediatrics, Nagoya University Graduate School of Medicine, Aichi, Japan., Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan., Koreth J; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Kröger N; Department for Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany., Ljungman P; Department. of Cellular Therapy and Allogeneic Stem Cell Transplantation. Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan., Popat U; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soiffer R; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Stefanski HE; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, USA., Kharfan-Dabaja MA; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Jun; Vol. 59 (6), pp. 832-837. Date of Electronic Publication: 2024 Mar 05.